Navigation Links
TGen Drug Development partners with Imaging Endpoints for comprehensive clinical trial services

SCOTTSDALE, Ariz. June 9, 2011 TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.

"The highest quality medical imaging provided by Imaging Endpoints is one more weapon in TD2's arsenal," said Dr. Stephen Gately, President of TD2, which assists drug developers in navigating the regulatory maze involved in the successful completion of clinical trials and bringing new therapeutics to market. "Our relationship is meant to help combine the best available technologies."

Imaging Endpoints will assist TD2 in the design and implementation of medical imaging analyses. Imaging Endpoints' expertise in anatomic and functional imaging will allow drug developers to best incorporate imaging into their clinical trials: probing molecular drug targets, assessing biologic responses and evaluating drug effectiveness.

"We hope that, through our new relationship with TD2, we will be able to assist oncology drug developers to maximize their return on investment in medical imaging during the course of their early-phase clinical trials," said Ron Korn, Medical Director of Imaging Endpoints. "Significant resources and time can be saved through wise and appropriate implementation of medical imaging."

The rapid completion of often time-consuming and costly clinical trials is needed to speed new treatments to the patients who need them, Dr. Gately said.

Scottsdale Mayor Jim Lane hailed the announcement by TD2 and Imaging Endpoints: "The partnership announced today between TD2 and Imaging Endpoints represents the merging of talents between two premier Scottsdale companies, and helps cement TD2 as a cornerstone of Scottsdale's growing biomedical industry."

Imaging holds the potential to predict outcomes, shorten the time needed to evaluate if a drug is hitting its target, and do so with relatively low risk to patients. By using specific imaging techniques, researchers can assess if new drug compounds are effective in such areas as anti-proliferation, metabolism and hypoxia.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related biology news :

1. Study finds widespread stream biodiversity declines at low levels of urban development
2. Development of a FRET sensor for real-time imaging of intracellular redox dynamics
3. Developmental disease is recreated in an adult model
4. Ulcer bacteria may contribute to development of Parkinsons disease
5. A study will enable the survival and growth of the 3 development phases of the European eel
6. Building brains: An introduction to neural development
7. Gene variant linked with development of COPD in men
8. Scientists find new class of compounds with great potential for research and drug development
9. New organic catalyst should enhance drug research and development
10. Brain development goes off track as vulnerable individuals develop schizophrenia
11. Study: Pace of brain development still strong in late teens
Post Your Comments:
(Date:11/17/2015)... Paris from 17 th until 19 th ... from 17 th until 19 th November 2015.   ... the first combined scanner in the world which scans both ... two different scanners were required: one for passports and one ... same surface. This innovation is an ideal solution for electronic ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... PHILADELPIA, PA (PRWEB) , ... November 24, 2015 , ... ... young entrepreneurs at competitive events in five states to develop and pitch their BIG ... student projects from each state are competing for votes to win the title of ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology: